Program
Bortezomib
Also written as “bortezomib”, “VELCADE” and “VELCADE TM (bortezomib) for Injection”.
Its studies are mostly in Multiple Myeloma · Carcinoma, Non-Small-Cell Lung · Lymphoma, Mantle-Cell · Lymphoma, Follicular · Amyloidosis, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 285 open or running | phase 4since Oct 15, 2014 | Sep 13, 2005 | Feb 14, 2029phase 3 · NCT04923893 |
| Takeda | 250 open or running | phase 4since Nov 18, 2005 | Oct 28, 2002 | none ahead |
| Oncotherapeutics | 40 open or running | phase 2since Apr 24, 2006 | Apr 19, 2006 | none ahead |
| AbbVie | 32 open or running | phase 3since Nov 28, 2023 | Aug 19, 2016 | Dec 2027phase 3 · NCT06158841 |
| AstraZeneca | 10 open or running | phase 4since Aug 23, 2023 | Aug 23, 2023 | none ahead |
| clinical-service-china | 10 open or running | phase 2since Mar 29, 2011 | Mar 29, 2011 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Jan 21, 2003.
- Oct 15, 2014Phase 4 study in Multiple MyelomaJohnson & Johnson · NCT02268890 · 18 enrolled · Taiwan
- May 26, 2016Phase 3 study in Multiple MyelomaJohnson & Johnson · NCT02811978 · 81 enrolled · China
- Aug 1, 2016Phase 2 study in Multiple MyelomaJohnson & Johnson · NCT02874742 · 224 enrolled · United States
- Aug 19, 2016AbbVie's first study: phase 2 study in Multiple MyelomaNew to AbbVieAbbVie · NCT02902965 · 74 enrolled · Czechia, Germany, Greece and more
- Oct 31, 2016Phase 2 study in Multiple MyelomaJohnson & Johnson · NCT02951819 · 101 enrolled · United States
- Oct 11, 2017Phase 2 study in Multiple MyelomaAbbVie · NCT03314181 · 156 enrolled · United States, Australia, Canada and more
- Nov 27, 2019Phase 3 study in Multiple MyelomaJohnson & Johnson · NCT04181827 · 419 enrolled · United States, Australia, Belgium and more
- Jun 10, 2021Phase 3 study in Multiple MyelomaJohnson & Johnson · NCT04923893 · 743 enrolled · United States, Argentina, Australia and more
- Oct 8, 2021Phase 3 study in Multiple MyelomaJohnson & Johnson · NCT05083169 · 587 enrolled · United States, Argentina, Belgium and more
- Sep 30, 2022Phase 2 study in Lymphoma, Mantle-CellJohnson & Johnson · NCT05564052 · 36 enrolled · Brazil, Czechia, Greece and more
- Oct 5, 2022Phase 3 study in Multiple MyelomaJohnson & Johnson · NCT05572515 · 614 enrolled · United States, Australia, Austria and more
- Aug 23, 2023AstraZeneca's first study: phase 4 study in HypophosphatasiaNew to AstraZenecaAstraZeneca · NCT06015750
- Nov 28, 2023Phase 3 study in Multiple MyelomaAbbVie · NCT06158841 · 421 enrolled · United States, Australia, Austria and more
- Aug 27, 2024Phase 2 study in Multiple MyelomaJohnson & Johnson · NCT06577025 · 43 enrolled · United States, Australia, Brazil and more
Ahead
- Dec 2027Primary completion: phase 3 study in Multiple MyelomaAbbVie · NCT06158841
- Feb 14, 2029Primary completion: phase 3 study in Multiple MyelomaJohnson & Johnson · NCT04923893
- Sep 2, 2030Primary completion: phase 2 study in Multiple MyelomaJohnson & Johnson · NCT06577025
- May 2031Primary completion: phase 2 study in Multiple MyelomaAbbVie · NCT03314181
TargetBeta
“26S proteasome inhibitor; 26S proteasome inhibitor”ChEMBL 37, by rule
Other programs on the same 38 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| carfilzomibrule | Amgen | phase 4 | 38 |
Studies
The newest 60 of 62 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06577025Multiple Myeloma · United States, Australia, Brazil and more | 2 | Active, not recruiting | Johnson & Johnson | Sep 2, 2030 | 43 |
| NCT06158841Multiple Myeloma · United States, Australia, Austria and more | 3 | Active, not recruiting | AbbVie | Dec 2027 | 421 |
| NCT06015750Hypophosphatasia | 4 | Withdrawn | AstraZeneca | Mar 13, 2030 | 0 |
| NCT05572515Multiple Myeloma · United States, Australia, Austria and more | 3 | Active, not recruiting | Johnson & Johnson | Oct 13, 2025 | 614 |
| NCT05564052Lymphoma, Mantle-Cell · Brazil, Czechia, Greece and more | 2 | Completed | Johnson & Johnson | Dec 6, 2023 | 36 |
| NCT05083169Multiple Myeloma · United States, Argentina, Belgium and more | 3 | Active, not recruiting | Johnson & Johnson | Aug 1, 2025 | 587 |
| NCT04923893Multiple Myeloma · United States, Argentina, Australia and more | 3 | Active, not recruiting | Johnson & Johnson | Feb 14, 2029 | 743 |
| NCT04181827Multiple Myeloma · United States, Australia, Belgium and more | 3 | Active, not recruiting | Johnson & Johnson | May 1, 2024 | 419 |
| NCT03314181Multiple Myeloma · United States, Australia, Canada and more | 2 | Active, not recruiting | AbbVie | May 2031 | 156 |
| NCT02951819Multiple Myeloma · United States | 2 | Completed | Johnson & Johnson | Mar 8, 2018 | 101 |
| NCT02902965Multiple Myeloma · Czechia, Germany, Greece and more | 2 | Completed | AbbVie | Oct 26, 2018 | 74 |
| NCT02874742Multiple Myeloma · United States | 2 | Completed | Johnson & Johnson | Jan 25, 2019 | 224 |
| NCT02811978Multiple Myeloma · China | 3 | Completed | Johnson & Johnson | May 7, 2018 | 81 |
| NCT02268890Multiple Myeloma · Taiwan | 4 | Completed | Johnson & Johnson | Jul 2015 | 18 |
| NCT01902862Lymphoma, Follicular · Germany | 2 | Terminated | Johnson & Johnson | Aug 2007 | 7 |
| NCT01801436Multiple Myeloma | 3 | Completed | Johnson & Johnson | Apr 2008 | 14 |
| NCT01910987Multiple Myeloma · Belgium, Finland, France and more | 3 | Completed | Johnson & Johnson | Feb 2016 | 80 |
| NCT01695330Multiple Myeloma · United States | 2 | Terminated | Oncotherapeutics | Oct 2015 | 5 |
| NCT01539083Multiple Myeloma · Australia, China, Korea, Republic of | 3 | Completed | Johnson & Johnson | Dec 30, 2015 | 256 |
| NCT01328236Leukemia, Plasma Cell · China | 2 | UNKNOWN | clinical-service-china | Sep 2013 | 20 |
| NCT01286077Multiple Myeloma · Austria, Czech Republic, Denmark and more | 2 | Completed | Johnson & Johnson | Nov 2012 | 106 |
| NCT01040871Lymphoma, Large B-Cell, Diffuse · Belgium | 2 | Completed | Takeda | Jun 2012 | 164 |
| NCT00985959Multiple Myeloma · Japan | 1 | Completed | Johnson & Johnson | Jun 2010 | 101 |
| NCT00931918Acromesomelic dysplasia, Maroteaux type · United States | 2 | Completed | Takeda | Aug 2015 | 206 |
| NCT00908232Multiple Myeloma · France, Germany, Greece and more | 2 | Completed | Johnson & Johnson | Aug 2011 | 163 |
| NCT00850499Lymphoma, Follicular · France, Germany, Greece and more | 2 | Terminated | Takeda | Sep 2011 | 12 |
| NCT00833560Multiple Myeloma · Germany | 2 | Completed | Johnson & Johnson | Jun 2009 | 401 |
| NCT00813150Multiple Myeloma · Germany | 3 | Completed | Johnson & Johnson | Jan 2013 | 96 |
| NCT00752518Multiple Myeloma | 2 | Completed | Johnson & Johnson | 35 | |
| NCT00742404Multiple Myeloma · United States | 2 | UNKNOWN | Oncotherapeutics | Jul 2010 | 35 |
| NCT00722137Lymphoma, Mantle-Cell · United States, Austria, Belgium and more | 3 | Completed | Takeda | Jan 1, 2014 | 487 |
| NCT00718640Multiple Myeloma · Canada | 2 | Terminated | Johnson & Johnson | Dec 2009 | 10 |
| NCT00715208Lymphoma, Follicular · United States, Puerto Rico | 2 | Completed | Takeda | Feb 2011 | 55 |
| NCT00706953Multiple Myeloma | 2 | Withdrawn | Johnson & Johnson | Jun 2010 | 0 |
| NCT00610792Ovarian Neoplasms · Italy, Switzerland | 2 | Withdrawn | Takeda | Sep 2009 | 91 |
| NCT00608907Multiple Myeloma · Israel, Italy, Poland and more | 1 | Completed | Takeda | Mar 2010 | 61 |
| NCT00561743Multiple Myeloma | 2 | Completed | Johnson & Johnson | May 2007 | 50 |
| NCT00531453Multiple Myeloma · Austria | 2 | Completed | Takeda | Apr 2009 | 98 |
| NCT00441168Multiple Myeloma · Croatia, Germany, Hungary and more | 2 | Terminated | Johnson & Johnson | Jan 2008 | 30 |
| NCT00431769Multiple Myeloma · Austria, Belgium, France and more | 2 | Completed | Johnson & Johnson | Feb 2009 | 130 |
| NCT00416273Multiple Myeloma · Germany | 3 | Completed | Johnson & Johnson | May 2013 | 217 |
| NCT00416208Multiple Myeloma · Germany | 3 | Completed | Johnson & Johnson | May 2013 | 154 |
| NCT00343720Carcinoma, Non-Small-Cell Lung · Belgium | 2 | Completed | Takeda | Oct 2007 | |
| NCT00317811Multiple Myeloma · United States | 2 | Completed | Oncotherapeutics | Feb 2009 | 35 |
| NCT00316940Multiple Myeloma · United States | 1 | Completed | Oncotherapeutics | Jun 2008 | 36 |
| NCT00312845Lymphoma, Non-Hodgkin · United States, Argentina, Australia and more | 3 | Completed | Takeda | Jun 2010 | 676 |
| NCT00298766Amyloidosis · United States | 2 | Completed | Takeda | Jul 2009 | 70 |
| NCT00283634NSCLC · United States | 2 | Terminated | Takeda | Jul 2007 | |
| NCT00257114Multiple Myeloma · United States | 4 | Completed | Takeda | Mar 2007 | |
| NCT00216697Multiple Myeloma | 2 | Completed | Johnson & Johnson | 13 | |
| NCT00129207Neoplasms · United States | 1 | Completed | Takeda | Sep 2006 | |
| NCT00117351Carcinoma, Non-Small-Cell Lung · United States | 2 | Terminated | Takeda | Jun 2007 | |
| NCT00111319Multiple Myeloma · United States | 3 | Completed | Takeda | Jul 2007 | |
| NCT00085696Lymphoma, B-Cell · United States | 2 | Completed | Takeda | Apr 2006 | 66 |
| NCT00080405Multiple Myeloma | 1 | Completed | Takeda | Jun 2005 | 40 |
| NCT00064636Advanced Non-Small Cell Lung Cancer | 1 | Terminated | Takeda | 46 | |
| NCT00064610Prostatic Neoplasms · United States | 2 | Completed | Takeda | Dec 2004 | 102 |
| NCT00063726Multiple Myeloma · United States, Austria, Belgium and more | 3 | Completed | Takeda | May 2005 | 600 |
| NCT00063713Lymphoma, Mantle-Cell · United States | 2 | Completed | Takeda | Dec 2005 | 152 |
| NCT00051987Colorectal Neoplasms · United States | 2 | Completed | Takeda | Mar 2004 | 175 |
How it is read
Names in the registry
- “Bortezomib”, 42 entries
- “bortezomib”, 18 entries
- “VELCADE”, 6 entries
- “VELCADE TM (bortezomib) for Injection”, 2 entries
- “VELCADE TM (bortezomib) for Injection, or PS-341”, 2 entries
Conditions, from the studies’ own filings
- Multiple Myeloma, 61 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Lymphoma, Mantle-Cell, 3 studies
- Lymphoma, Follicular, 3 studies
- Amyloidosis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.